NCI launches public-private lung cancer study

The National Cancer Institute is sponsoring a collaborative clinical trial called the Lung Cancer Master Protocol, or Lung-MAP, for patients with squamous cell carcinoma. Foundation Medicine's genetic-sequencing technology will be used to screen patients for genetic alterations that might be related to their cancer, and patients will be randomly grouped into one of five treatment arms. Participants include the Foundation for the NIH, SWOG Cancer Research, Friends of Cancer Research, Amgen, Genentech, Pfizer, AstraZeneca and its MedImmune unit, the Bonnie J. Addario Lung Cancer Foundation, the American Cancer Society, Free to Breathe, the Lung Cancer Alliance, LUNGevity and Uniting Against Lung Cancer.

View Full Article in:

GenomeWeb Daily News (free registration) · Oncology Report, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI